1237535-76-0

Usage

Uses

Used in Organic Synthesis:
Tert-butyl 4-fluoropyridin-2-ylcarbamate is utilized as a key intermediate in organic synthesis for the preparation of a variety of chemical compounds. Its unique structure allows for the creation of diverse molecules with potential applications in various fields.
Used in Medicinal Chemistry:
In the realm of medicinal chemistry, tert-butyl 4-fluoropyridin-2-ylcarbamate is employed as a building block for the synthesis of pharmaceuticals. Its incorporation into drug molecules can contribute to the development of new therapeutic agents with improved efficacy and selectivity.
Used in Agrochemicals:
Tert-butyl 4-fluoropyridin-2-ylcarbamate also finds use in the agrochemical industry, where it is used as a precursor for the synthesis of pesticides and other agrochemical products. Its versatility enables the creation of compounds with targeted pest control properties.
Used in Biological Research:
tert-butyl 4-fluoropyridin-2-ylcarbamate is studied for its potential biological activity, including antitumor and antiviral properties. Researchers explore its interactions with biological systems to understand its therapeutic potential and possible applications in medicine.
Used in Drug Development:
Tert-butyl 4-fluoropyridin-2-ylcarbamate is used in drug development as a structural component of new pharmaceutical entities. Its unique attributes may contribute to the discovery of innovative drugs with enhanced pharmacological profiles.

Upstream product

• 34941-91-8 2-chloro-4-fluoropyridine 
• 4248-19-5 tert-butyl carbazate 
• 944401-77-8 4-fluoropyridin-2-amine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 944401-69-8 5-bromo-4-fluoro-pyridin-2-ylamine 
• 1159827-76-5 7-fluoroimidazo[1,2-a]pyridine-3-carboxylic acid 
• 1313408-99-9 ethyl 7-fluoroimidazo[1,2-a] pyridine-3-carboxylate 
• 1237535-78-2 5-fluoro-3,4-dihydro-1,8-naphthyridine-2(1H)-one 

Relevant academic research and scientific papers

CHIRAL SYNTHESIS OF FUSED BICYCLIC RAF INHIBITORS

The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitor enantiomers of formula (I), (Ia), (Ib), (II), (IIa), or (IIb), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, with high enantiomeric excess (%ee). The disclosure also relates to method of using the compound of formula (I), (Ia), (Ib), (II), (IIa), or (IIb), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.

FUSED BICYCLIC RAF INHIBITORS AND METHODS FOR USE THEREOF

The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method o

FARNESOID X RECEPTOR AGONISTS AND USES THEREOF

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

STABLE SOLID DISPERSIONS OF B-RAF KINASE DIMER INHIBITOR, METHODS OF PREPARATION, AND USES THEREFOR

Disclosed herein is a physically stable solid dispersion comprising Compound 1, i.e., the B-RAF kinase dimer inhibitor 1- ( (1S, 1aS, 6bS) -5- ( (7-oxo-5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-4-yl) oxy) -1a,6b-dihydro-1H-cyclopropa [b] benzofuran-1-yl) -3- (2, 4, 5-trifluorophenyl) urea and a specific stabilizing polymer, the method for preparing the same, and the uses of the solid dispersion. Also disclosed herein is the crystalline form of Compound 1.

Method suitable for large-scale production of B-RAF kinase dimer inhibitor

The invention relates to a method for large-scale production of a B-RAF kinase dimer inhibitor 1-((1S, 1aS, 6bS)-5-((7-oxo-5, 6, 7, 8-tetrahydro-1, 8-diazanaphthalene-4-yl) oxy)-1a, 6b-dihydro-1H-cyclopropyl [b] benzofuran-1-yl)-3-(2, 4, 5- trifluorophenyl) urea (hereinafter sometimes referred to as a compound 1). The method enables impurities or by-products to be controlled to 0.05% or less without the use of expensive column chromatography operations. Thus, the method greatly reduces cost and is suitable for large-scale production.

Stable crystalline form A of B-RAF kinase dimer inhibitor

The invention relates to a stable crystalline form A of a B-RAF kinase dimer inhibitor 1-((1S, 1aS, 6bS)-5-((7-oxo-5, 6, 7, 8-tetrahydro-1, 8-diazanaphthalene-4-yl) oxy)-1a, 6b-dihydro-1H-cyclopropyl[b] benzofuran-1-yl)-3-(2, 4, 5- trifluorophenyl) urea (hereinafter sometimes referred to as a compound 1), a preparation method of the crystalline Form A and therapeutic use of the crystalline Form A.

Amorphous B-RAF kinase dimer inhibitor

The invention relates to a stable amorphous form of a B-RAF kinase dimer inhibitor 1-((1S, 1aS, 6bS)-5-((7-oxo-5, 6, 7, 8-tetrahydro-1, 8-diazanaphthalene-4-yl) oxy)-1a, 6b-dihydro-1H-cyclopropyl [b]benzofuran-1-yl)-3-(2, 4, 5- trifluorophenyl) urea (hereinafter sometimes referred to as a compound 1), a prepration method of the amorphous compound and therapeutic use of the amorphous compound.

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of substituted 5,6,7,8-tetrahydroimidazo[l,2-α]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory di

IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY

A series of imidazo[l,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.